Trial Profile
Trabectedin and Irinotecan in Pediatric Refractory Sarcomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary) ; Irinotecan; Irinotecan
- Indications Sarcoma
- Focus Adverse reactions
- Acronyms TrIPReSarc
- 29 Jul 2015 New trial record